Leukotrienes Are Upregulated and Associated with Human T-Lymphotropic Virus Type 1 (HTLV-1)-Associated Neuroinflammatory Disease

Leukotrienes (LTs) are lipid mediators involved in several inflammatory disorders. We investigated the LT pathway in human T-lymphotropic virus type 1 (HTLV-1) infection by evaluating LT levels in HTLV-1-infected patients classified according to the clinical status as asymptomatic carriers (HACs) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Bioactive LTB4 and CysLTs were both increased in the plasma and in the supernatant of peripheral blood mononuclear cell cultures of HTLV-1-infected when compared to non-infected. Interestingly, CysLT concentrations were increased in HAM/TSP patients. Also, the concentration of plasma LTB4 and LTC4 positively correlated with the HTLV-1 proviral load in HTLV-1-infected individuals. The gene expression levels of LT receptors were differentially modulated in CD4+ and CD8+ T cells of HTLV-1-infected patients. Analysis of the overall plasma signature of immune mediators demonstrated that LT and chemokine amounts were elevated during HTLV-1 infection. Importantly, in addition to CysLTs, IP-10 was also identified as a biomarker for HAM/TSP activity. These data suggest that LTs are likely to be associated with HTLV-1 infection and HAM/TSP development, suggesting their putative use for clinical monitoring.

[1]  M. Peters-Golden,et al.  Leukotrienes and airway inflammation. , 2011, Biochimica et biophysica acta.

[2]  Mardge H. Cohen,et al.  The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women , 2011, AIDS.

[3]  Ana Carolina Campi-Azevedo,et al.  Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. , 2011, The Journal of infectious diseases.

[4]  Changsheng Du,et al.  Antiasthmatic Drugs Targeting the Cysteinyl Leukotriene Receptor 1 Alleviate Central Nervous System Inflammatory Cell Infiltration and Pathogenesis of Experimental Autoimmune Encephalomyelitis , 2011, The Journal of Immunology.

[5]  L. Faccioli,et al.  Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[6]  F. Bosetti,et al.  Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  G. Ippolito,et al.  IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy , 2011, BMC infectious diseases.

[8]  E. Donadi,et al.  HLA-G 14-bp insertion/deletion polymorphism is a risk factor for HTLV-1 infection. , 2011, AIDS research and human retroviruses.

[9]  Y. Yamano,et al.  Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis , 2003, Journal of NeuroVirology.

[10]  S. Akiba,et al.  HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: Analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years , 2001, Journal of NeuroVirology.

[11]  O. Martins-Filho,et al.  Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  D. Goletti,et al.  IP-10 detection in urine is associated with lung diseases , 2010, BMC infectious diseases.

[13]  F. Balkwill,et al.  Human T-Lymphotropic Virus Type 1-Induced CC Chemokine Ligand 22 Maintains a High Frequency of Functional FoxP3+ Regulatory T Cells , 2010, The Journal of Immunology.

[14]  F. Proietti,et al.  Epidemiology, Treatment, and Prevention of Human T-Cell Leukemia Virus Type 1-Associated Diseases , 2010, Clinical Microbiology Reviews.

[15]  M. Fukayama,et al.  The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. , 2010, Biochemical and biophysical research communications.

[16]  H. Yamanaka,et al.  Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain , 2009, Glia.

[17]  S. Izumo.  The 50th Anniversary of Japanese Society of Neuropathology Memorial Symposium: Milestones in Neuropathology from Japan Neuropathology of HTLV-1-associated myelopathy (HAM/TSP) , 2010 .

[18]  G. Taylor,et al.  The neurology of HTLV-1 infection , 2009, Practical Neurology.

[19]  C. Sorgi,et al.  Leukotrienes Are Potent Adjuvant during Fungal Infection: Effects on Memory T Cells1 , 2008, The Journal of Immunology.

[20]  J. Gosselin,et al.  Leukotriene B4 Induces Release of Antimicrobial Peptides in Lungs of Virally Infected Mice1 , 2008, The Journal of Immunology.

[21]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[22]  N. Flamand,et al.  Leukotrienes: Mediators that have been typecast as villains , 2007, Cellular and Molecular Life Sciences.

[23]  M. Thompson,et al.  Cysteinyl‐leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends , 2007, Medicinal research reviews.

[24]  M. Tremblay,et al.  Leukotriene B4 Triggers the In Vitro and In Vivo Release of Potent Antimicrobial Agents1 , 2007, The Journal of Immunology.

[25]  Anne-Mieke Vandamme,et al.  Human T-lymphotropic virus 1: recent knowledge about an ancient infection. , 2007, The Lancet. Infectious diseases.

[26]  C. Sorgi,et al.  Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. , 2007, Microbes and infection.

[27]  G. Vanham,et al.  Proviral load and immune markers associated with human T‐lymphotropic virus type 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru , 2006, Clinical and experimental immunology.

[28]  J. Ho,et al.  Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV‐1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV‐1 carrier state , 2006, Clinical and experimental immunology.

[29]  A. Lézin,et al.  HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: A marker of disease progression , 2005, Journal of the Neurological Sciences.

[30]  Eleuza R Machado,et al.  Leukotrienes Play a Role in the Control of Parasite Burden in Murine Strongyloidiasis1 , 2005, The Journal of Immunology.

[31]  T. Ichiyama,et al.  Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[32]  L. Flamand,et al.  Release of anti-HIV mediators after administration of leukotriene B4 to humans. , 2004, The Journal of infectious diseases.

[33]  E. Carvalho,et al.  Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers , 2004, BMC infectious diseases.

[34]  L. Faccioli,et al.  Blockade of Endogenous Leukotrienes Exacerbates Pulmonary Histoplasmosis , 2004, Infection and Immunity.

[35]  M. Shingu,et al.  Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids , 1991, Inflammation.

[36]  Jilly F. Evans,et al.  International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors , 2003, Pharmacological Reviews.

[37]  E. Carvalho,et al.  Cytokine Profile and Immunomodulation in Asymptomatic Human T‐Lymphotropic Virus Type 1‐Infected Blood Donors , 2001, Journal of acquired immune deficiency syndromes.

[38]  M. Moriuchi,et al.  Reciprocal Interactions between Human T-Lymphotropic Virus Type 1 and Prostaglandins: Implications for Viral Transmission , 2001, Journal of Virology.

[39]  S. Cinti,et al.  Granulocyte-macrophage colony-stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocytes and neutrophils in acquired immunodeficiency syndrome. , 1999, Blood.

[40]  Toshiki Watanabe,et al.  HTLV-1-associated diseases. , 1997, International journal of hematology.

[41]  K. Badr,et al.  Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. , 1997, Kidney international.

[42]  T. Masuyama,et al.  Leukotriene B4 and C4 in cerebrospinal fluid from children with meningitis and febrile seizures. , 1996, Pediatric neurology.

[43]  S. McColl,et al.  Granulocyte-macrophage colony-stimulating factor enhances 5-lipoxygenase levels in human polymorphonuclear leukocytes. , 1994, Journal of immunology.

[44]  A. Wildfeuer,et al.  Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients , 1992, Acta neurologica Scandinavica.

[45]  A. Lazzarin,et al.  Mediator release in cerebrospinal fluid of human immunodeficiency virus-positive patients with central nervous system involvement , 1992, Journal of Neuroimmunology.

[46]  P. Jakobsson,et al.  Leukotriene B4 in the immune system. , 1992, International journal of immunopharmacology.

[47]  M. Baulac,et al.  Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. , 1990, The New England journal of medicine.

[48]  K. Austen,et al.  The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. , 1984, The Journal of clinical investigation.